Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA) Income Statement


Akebia Therapeutics Income Statement

Last quarter (Q1 2024), Akebia Therapeutics's total revenue was $32.61M, a decrease of -18.74% from the same quarter last year. In Q1, Akebia Therapeutics's net income was $-17.98M. See Akebia Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 172.97M$ 194.62M$ 292.60M$ 213.58M$ 295.31M$ 335.00M
Cost of Revenue
$ 66.27M$ 74.15M$ 84.80M$ -153.39M$ 295.91M$ 145.34M
Gross Profit
$ 129.84M$ 120.47M$ 207.81M$ 213.58M$ -601.00K$ 189.66M
Operating Expense
$ 157.09M$ 166.73M$ 286.92M$ -325.50M$ 375.84M$ 475.95M
Operating Income
$ -34.45M$ -46.26M$ -79.11M$ -265.32M$ -376.44M$ -286.29M
Net Non Operating Interest Income Expense
$ -6.97M$ -6.03M$ -15.69M$ -19.94M$ -8.87M$ 792.00K
Other Income Expense
$ 470.00K$ -363.00K$ -2.24M$ -2.41M$ 1.86M$ -794.00K
Pretax Income
$ -44.83M$ -51.92M$ -92.56M$ -282.84M$ -383.46M$ -286.29M
Tax Provision
----$ 0.00$ -6.63M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -43.69M$ -51.92M$ -86.21M$ -282.84M$ -383.46M$ -279.66M
Basic EPS
$ -0.23$ -0.28$ -0.51$ -1.70$ -2.77$ -2.36
Diluted EPS
$ -0.23$ -0.28$ -0.51$ -1.70$ -2.77$ -2.36
Basic Average Shares
$ 770.05M$ 187.47M$ 182.78M$ 165.95M$ 138.46M$ 118.40M
Diluted Average Shares
$ 770.05M$ 187.47M$ 182.78M$ 165.95M$ 138.46M$ 118.40M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 223.36M$ 240.88M$ -371.72M$ -478.90M$ 671.75M$ 621.29M
Net Income From Continuing And Discontinued Operation
$ -43.69M$ -51.92M$ -92.56M$ -282.84M$ -383.46M$ -279.66M
Normalized Income
$ -47.29M$ -40.22M--$ -383.46M$ -279.66M
Interest Expense
$ -44.12M$ -45.89M$ -92.56M$ -282.84M$ -376.44M$ -286.29M
$ -8.75M$ -4.05M$ -54.87M$ -244.88M$ -342.85M$ -247.64M
Currency in USD

Akebia Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis